1. Triamcinolone Acetonide Aqueous Nasal Inhaler for the Treatment of Spring Grass Seasonal Allergic Rhinitis in Children
- Author
-
Eric J. Schenkel, Gary Gross, Kraig Jacobson, Roger H. Kobayashi, Anne M. Savacool, Brandon Simpson, Joseph A. Smith, and Guy A. Settipane
- Subjects
Pulmonary and Respiratory Medicine ,Triamcinolone acetonide ,Dose ,business.industry ,Inhaler ,Nasal itching ,respiratory system ,Placebo ,Eye symptoms ,Anesthesia ,Pediatrics, Perinatology and Child Health ,otorhinolaryngologic diseases ,medicine ,Immunology and Allergy ,Once daily ,business ,Pediatric population ,medicine.drug - Abstract
Triamcinolone acetonide (TAA) Aqueous nasal inhaler is an effective and well-tolerated treatment for the symptoms associated with seasonal allergic rhinitis (SAR). This study compared the safety and efficacy of once-daily administration of TAA Aqueous nasal inhaler (110 μg and 220 μg) with placebo in a pediatric population with spring-grass SAR. Two hundred and twenty-three patients (6-11 years of age) were evaluated in this randomized, placebo-controlled, double-blinded trial. Patients received TAA Aqueous nasal inhaler (110 μg or 220 μg) or placebo once daily for 2 weeks. Rhinitis symptoms (nasal stuffiness, discharge, sneezing, nasal index, nasal itching, and eye symptoms) were evaluated and recorded daily. Both TAA Aqueous nasal inhaler dosages were more effective than placebo in relieving the symptoms of SAR over the 2-week treatment period. Patients in the 110-μg group had significantly (P < 0.05) greater mean reductions in nasal stuffiness, nasal discharge, and nasal index compared to placebo after...
- Published
- 1997
- Full Text
- View/download PDF